GlycoMimetics Inc. | Ownership
Companies that own GlycoMimetics Inc.
Wellington Management Co. LLP
5,592,390
12.99%
-195,064
0.02%
06/30/2018
OppenheimerFunds, Inc.
4,426,923
10.28%
1,465,729
0.04%
08/31/2018
T. Rowe Price Associates, Inc.
3,447,508
8.01%
576,733
0.01%
06/30/2018
BlackRock Fund Advisors
2,613,100
6.07%
1,656,106
0%
06/30/2018
Fidelity Management & Research Co.
2,477,963
5.76%
4,013
0%
06/30/2018
Franklin Advisers, Inc.
2,163,825
5.03%
55,646
0.02%
06/30/2018
Redmile Group LLC
2,029,347
4.71%
-252,921
0.93%
06/30/2018
SSgA Funds Management, Inc.
1,925,184
4.47%
232,206
0%
06/30/2018
The Vanguard Group, Inc.
1,595,844
3.71%
85,976
0%
06/30/2018
Jennison Associates LLC
1,593,857
3.7%
26,236
0.02%
06/30/2018
| Address |
9708 Medical Center Drive
Rockville Maryland 20850
United States
|
|
Employees
|
- |
| Website |
http://www.glycomimetics.com |
| Updated |
07/08/2019 |
| GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. |
